
Sign up to save your podcasts
Or


In this podcast, Dr. Andrew Ko discusses the SIRFLOX trial evaluating whether the addition of radioembolization to systemic chemotherapy confers any benefit in patients with liver-dominant metastatic colorectal cancer, and whether the results should compel us to rethink our use of this technology for this disease indication.
By American Society of Clinical Oncology (ASCO)3.8
3939 ratings
In this podcast, Dr. Andrew Ko discusses the SIRFLOX trial evaluating whether the addition of radioembolization to systemic chemotherapy confers any benefit in patients with liver-dominant metastatic colorectal cancer, and whether the results should compel us to rethink our use of this technology for this disease indication.

14,359 Listeners

139 Listeners

319 Listeners

498 Listeners

58 Listeners

112,751 Listeners

44 Listeners

32 Listeners

195 Listeners

91 Listeners

363 Listeners

253 Listeners

189 Listeners

41 Listeners

613 Listeners